In the midst of this new bull market, one group of stocks is writhing in pain: pharmaceuticals. Are we hearing a death knell — or is it a dinner bell?

I’m inclined to press the button for Option #2. Granted, all the major drug makers are facing issues with patent expirations in the next couple of years.